Early modulation of pro-inflammatory microglia by minocycline loaded nanoparticles confers long lasting protection after spinal cord injury
Source abstract
Abstract
Many efforts have been performed in order to understand the role of recruited macrophages in the progression of spinal cord injury (SCI). Different studies revealed a pleiotropic effect played by these cells associated to distinct phenotypes (M1 and M2), showing a predictable spatial and temporal distribution in the injured site after SCI. Differently, the role of activated microglia in injury progression has been poorly investigated, mainly because of the challenges to target and selectively modulate them in situ. A delivery nanovector tool (poly-ε-caprolactone-based nanoparticles) able to selectively treat/target microglia has been developed and used here to clarify the temporal and spatial involvement of the pro-inflammatory response associated to microglial cells in SCI. We show that a treatment with nanoparticles loaded with minocycline, the latter a well-known anti-inflammatory drug, when administered acutely in a SCI mouse model is able to efficiently modulate the resident microglial cells reducing the pro-inflammatory response, maintaining a pro-regenerative milieu and ameliorating the behavioral outcome up to 63 days post injury. Furthermore, by using this selective delivery tool we demonstrate a mechanistic link between early microglia activation and M1 macrophages recruitment to the injured site via CCL2 chemokine, revealing a detrimental contribution of pro-inflammatory macrophages to injury progression after SCI.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Spinal Cord Injury Research · Neuroinflammation and Neurodegeneration Mechanisms · Immune cells in cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (46)
Show source-provided references
1. Central nervous system regenerative failure: role of oligodendrocytes, astrocytes, and microglia
2. Macrophage activation and its role in repair and pathology after spinal cord injury10.1016/j.brainres.2014.12.045 ↗
3. Inflammatory pathways in spinal cord injury10.1016/B978-0-12-407178-0.00006-5 ↗
4. Harnessing monocyte-derived macrophages to control central nervous system pathologies: no longer 'if' but 'how'10.1002/path.4106 ↗
5. Neuroinflammation in spinal cord injury: therapeutic targets for neuroprotection and regeneration10.1016/S0079-6123(09)17508-8 ↗
6. Temporal changes in monocyte and macrophage subsets and microglial macrophages following spinal cord injury in the Lys-Egfp-ki mouse model10.1016/j.jneuroim.2013.04.008 ↗
7. Chronic exposure to TGFbeta1 regulates myeloid cell inflammatory response in an IRF7-dependent manner10.15252/embj.201489293 ↗
8. Glial scar and immune cell involvement in tissue remodeling and repair following acute CNS injuries10.1002/glia.22676 ↗
9. Repertoire of microglial and macrophage responses after spinal cord injury10.1038/nrn3053 ↗
10. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord10.1523/JNEUROSCI.3257-09.2009 ↗
11. Current options for drug delivery to the spinal cord10.1517/17425247.2013.751372 ↗
12. Differential uptake of functionalized polystyrene nanoparticles by human macrophages and a monocytic cell line10.1021/nn2000756 ↗
13. Nanovector-mediated drug delivery for spinal cord injury treatment10.1002/wnan.1276 ↗
14. Polymeric nanoparticle system to target activated microglia/macrophages in spinal cord injury10.1016/j.jconrel.2013.11.001 ↗
15. Selective nanovector mediated treatment of activated proinflammatory microglia/macrophages in spinal cord injury10.1021/nn4036014 ↗
16. Multifunctionalized CMCht/PAMAM dendrimer nanoparticles modulate the cellular uptake by astrocytes and oligodendrocytes in primary cultures of glial cells10.1002/mabi.201100294 ↗
17. Nanocarrier-mediated inhibition of macrophage migration inhibitory factor attenuates secondary injury after spinal cord injury10.1021/nn505980z ↗
18. Targeted drug delivery to macrophages10.1517/17425247.2013.751370 ↗
19. The role of the microglia in acute CNS injury10.1007/s11011-014-9531-6 ↗
20. Bone marrow mesenchymal stromal cells drive protective M2 microglia polarization after brain trauma10.1007/s13311-014-0277-y ↗
21. Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury10.1111/j.1471-4159.2006.03799.x ↗
22. Minocycline selectively inhibits M1 polarization of microglia10.1038/cddis.2013.54 ↗
23. Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat10.1089/089771503770195867 ↗
24. Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury10.1073/pnas.0306239101 ↗
25. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice10.1093/brain/awg178 ↗
26. Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor production in microglia after spinal cord injury10.1523/JNEUROSCI.1661-07.2007 ↗
27. epsilon-Caprolactone-based macromonomers suitable for biodegradable nanoparticles synthesis through free radical polymerization10.1021/ma201955p ↗
28. Basso mouse scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains10.1089/neu.2006.23.635 ↗
29. Three-dimensional imaging of solvent-cleared organs using 3DISCO10.1038/nprot.2012.119 ↗
30. Ultramicroscopy: three-dimensional visualization of neuronal networks in the whole mouse brain10.1038/nmeth1036 ↗
31. Morphological features and responses to AMPA receptor-mediated excitotoxicity of mouse motor neurons: comparison in purified, mixed anterior horn or motor neuron/glia cocultures10.1016/j.jneumeth.2007.12.022 ↗
32. Neuroprotective effects of toll-like receptor 4 antagonism in spinal cord cultures and in a mouse model of motor neuron degeneration10.2119/molmed.2012.00020 ↗
33. The isolation and characterization of murine macrophages10.1002/0471142735.im1401s83 ↗
34. mu-Slide Chemotaxis: a new chamber for long-term chemotaxis studies10.1186/1471-2121-12-21 ↗
35. Synthesis of surfactant free PCL-PEG brushed nanoparticles with tunable degradation kinetics10.1016/j.ijpharm.2013.06.020 ↗
36. Recruitment of beneficial M2 macrophages to injured spinal cord is orchestrated by remote brain choroid plexus10.1016/j.immuni.2013.02.012 ↗
37. In vivo longitudinal MRI and behavioral studies in experimental spinal cord injury10.1089/neu.2010.1369 ↗
38. Genetic targeting of microglia10.1002/glia.22727 ↗
39. Activated microglia contribute to the maintenance of chronic pain after spinal cord injury10.1523/JNEUROSCI.0003-06.2006 ↗
40. Quantitative analysis of cellular inflammation after traumatic spinal cord injury: evidence for a multiphasic inflammatory response in the acute to chronic environment10.1093/brain/awp322 ↗
41. Stimulation of monocytes, macrophages, and microglia by amphotericin B and macrophage colony-stimulating factor promotes remyelination10.1523/JNEUROSCI.1797-14.2015 ↗
42. High-resolution intravital imaging reveals that blood-derived macrophages but not resident microglia facilitate secondary axonal dieback in traumatic spinal cord injury10.1016/j.expneurol.2014.01.013 ↗
43. Blockade of interleukin-6 signaling inhibits the classic pathway and promotes an alternative pathway of macrophage activation after spinal cord injury in mice10.1186/1742-2094-9-40 ↗
44. Adoptive transfer of M2 macrophages promotes locomotor recovery in adult rats after spinal cord injury10.1016/j.bbi.2014.11.007 ↗
45. Microglial physiopathology: how to explain the dual role of microglia after acute neural disorders?10.1002/brb3.51 ↗
46. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury10.1523/JNEUROSCI.5275-03.2004 ↗